BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 28913735)

  • 1. Efficacy and Safety of Tazarotene 0.1% Plus Clindamycin 1% Gel Versus Adapalene 0.1% Plus Clindamycin 1% Gel in Facial Acne Vulgaris: A Randomized, Controlled Clinical Trial.
    Maiti R; Sirka CS; Ashique Rahman MA; Srinivasan A; Parida S; Hota D
    Clin Drug Investig; 2017 Nov; 37(11):1083-1091. PubMed ID: 28913735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
    Thiboutot D; Arsonnaud S; Soto P
    J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris.
    Tanghetti E; Dhawan S; Torok H; Kircik L
    Dermatol Online J; 2007 Jul; 13(3):1. PubMed ID: 18328195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy.
    Draelos ZD; Tanghetti EA;
    Cutis; 2002 Feb; 69(2 Suppl):20-9. PubMed ID: 12095065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative irritancy comparison of topical retinoid and antimicrobial combination therapies.
    Dosik JS; Gilbert RD; Arsonnaud S
    Skinmed; 2006; 5(5):219-23. PubMed ID: 16957432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.
    Tanghetti E; Abramovits W; Solomon B; Loven K; Shalita A
    J Drugs Dermatol; 2006 Mar; 5(3):256-61. PubMed ID: 16573259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed-dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: A multicenter, randomized, investigator-blind, parallel-group study.
    Hayashi N; Kurokawa I; Siakpere O; Endo A; Hatanaka T; Yamada M; Kawashima M
    J Dermatol; 2018 Aug; 45(8):951-962. PubMed ID: 29905384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Del Rosso J; Draelos Z; Leyden J; Shalita A; Glaser DA; Grimes P; Webster G; Barnett P; Le Gall N
    J Drugs Dermatol; 2010 May; 9(5):549-58. PubMed ID: 20480800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.
    Webster GF; Guenther L; Poulin YP; Solomon BA; Loven K; Lee J
    Cutis; 2002 Feb; 69(2 Suppl):4-11. PubMed ID: 12095066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study.
    Stein Gold L; Weiss J; Rueda MJ; Liu H; Tanghetti E
    Am J Clin Dermatol; 2016 Jun; 17(3):293-303. PubMed ID: 26945741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is switching retinoids a sound strategy for the treatment of acne vulgaris?
    Gold LS; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s11-7. PubMed ID: 18575221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial.
    Leyden J; Lowe N; Kakita L; Draelos Z
    Cutis; 2001 Jun; 67(6 Suppl):10-6. PubMed ID: 11499327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a nano-emulsion gel formulation of adapalene 0.1% and clindamycin 1% combination in acne vulgaris: a randomized, open label, active-controlled, multicentric, phase IV clinical trial.
    Prasad S; Mukhopadhyay A; Kubavat A; Kelkar A; Modi A; Swarnkar B; Bajaj B; Vedamurthy M; Sheikh S; Mittal R
    Indian J Dermatol Venereol Leprol; 2012; 78(4):459-67. PubMed ID: 22772617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris.
    Pariser D; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s18-23. PubMed ID: 18575222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
    Stein Gold L; Baldwin H; Kircik LH; Weiss JS; Pariser DM; Callender V; Lain E; Gold M; Beer K; Draelos Z; Sadick N; Pillai R; Bhatt V; Tanghetti EA
    Am J Clin Dermatol; 2022 Jan; 23(1):93-104. PubMed ID: 34674160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris.
    Kakita L
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S51-4. PubMed ID: 10898831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%.
    Zhang JZ; Li LF; Tu YT; Zheng J
    J Dermatolog Treat; 2004 Dec; 15(6):372-8. PubMed ID: 15764049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
    J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
    Feldman SR; Werner CP; Alió Saenz AB
    J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tolerability profile of clindamycin 1%/benzoyl peroxide 5% gel vs. adapalene 0.1%/benzoyl peroxide 2.5% gel for facial acne: results of a randomized, single-blind, split-face study.
    Gonzalez P; Vila R; Cirigliano M
    J Cosmet Dermatol; 2012 Dec; 11(4):251-60. PubMed ID: 23174047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.